NIFK Activators
NIFK Activators are a unique collection of chemical compounds that indirectly initiate the enhancement of NIFK's functional activity by modulating specific intracellular signaling cascades. Forskolin, a direct adenylate cyclase stimulator, along with 8-Bromo-cAMP and Dibutyryl cAMP, both resistant to degradation and effective at elevating intracellular cAMP levels, lead to the activation of protein kinase A (PKA). PKA, in turn, phosphorylates NIFK, which is a process that directly enhances NIFK's functional activity. Sildenafil and Zaprinast, which inhibit PDE5, along with Rolipram, Cilostamide, and Milrinone, which target PDE3 and PDE4, respectively, elevate intracellular cAMP or cGMP levels. Elevated cyclic nucleotide levels result in the activation of PKA, further promoting the phosphorylation and enhancement of NIFK's activity.
Moreover, agents such as Epac activator 007-AM specifically enable Epac-mediated pathways, leading to alterations in cellular processes that augment the activity of NIFK independently of the PKA route. Anagrelide and Vinpocetine, by inhibiting PDE3 and PDE1, respectively, also contribute to the accumulation of cAMP, fortifying the PKA signaling cascade and reinforcing the phosphorylation-dependent activation of NIFK.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylate cyclase, leading to an increase in intracellular cAMP levels. Elevated cAMP activates PKA, which can phosphorylate NIFK, thereby enhancing its functional activity within the cell. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA. PKA activation can lead to the phosphorylation of NIFK, increasing its functional activity in processes that NIFK is involved in. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, which prevents the breakdown of cAMP, thus increasing its concentration in the cell. Higher cAMP levels lead to PKA activation, which in turn can enhance the activity of NIFK by phosphorylation. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl cAMP is another cAMP analog that is resistant to degradation by phosphodiesterase and thus effectively raises intracellular cAMP levels, activating PKA. Activated PKA can phosphorylate and enhance the activity of NIFK. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, particularly PDE5, leading to increased cGMP levels which can enhance cAMP signaling. This increase in cAMP may activate PKA, which has the potential to phosphorylate and activate NIFK. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is an inhibitor of phosphodiesterase 4 (PDE4), leading to increased cAMP levels. The resultant activation of PKA can enhance the activity of NIFK through phosphorylation. | ||||||
Anagrelide hydrochloride | 58579-51-4 | sc-203513 sc-203513A | 10 mg 50 mg | $103.00 $587.00 | 1 | |
Anagrelide inhibits PDE3, leading to an increase in cAMP levels in the cell. This elevation can activate PKA, which in turn may phosphorylate and enhance the activity of NIFK. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective inhibitor of PDE3, which increases cAMP levels, leading to the activation of PKA. PKA then potentially phosphorylates NIFK, enhancing its cellular activity. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a PDE1 inhibitor that elevates cAMP and cGMP levels in the cell, indirectly promoting PKA activation. This can lead to the phosphorylation and activation of NIFK. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone is a selective PDE3 inhibitor that increases cAMP levels in the cell. Elevated cAMP can activate PKA, which may then phosphorylate and enhance the activity of NIFK. | ||||||